Wealthedge Investment Advisors Invests $965K in Vertex Pharmaceuticals

The institutional investor purchased 2,465 shares of the pharmaceutical company's stock.

Mar. 3, 2026 at 7:15am

Got story updates? Submit your updates here. ›

Wealthedge Investment Advisors LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to the company's recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,465 shares of the pharmaceutical company's stock, valued at approximately $965,000.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many people with the disease. Wealthedge's investment in Vertex reflects the firm's confidence in the company's continued growth and innovation.

The details

According to the 13F filing, Wealthedge Investment Advisors LLC purchased the 2,465 shares of Vertex Pharmaceuticals during the third quarter. The shares were valued at approximately $965,000. This new stake in Vertex adds to the institutional investor's portfolio, which likely includes other healthcare and pharmaceutical companies.

  • Wealthedge Investment Advisors LLC purchased the Vertex Pharmaceuticals shares during the third quarter.

The players

Wealthedge Investment Advisors LLC

An institutional investment firm that purchased a new stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Wealthedge's investment in Vertex Pharmaceuticals reflects the firm's confidence in the company's continued growth and innovation in developing transformative therapies for serious diseases like cystic fibrosis.